Метаболомная диагностическая технология как основа формирования принципов метаболического здоровья

Цель: рассмотреть современные данные о ключевых метаболических изменениях, отражающих основные патогенетические оси метаболического синдрома (МС), и оценить их потенциал для диагностики и стратификации МС.

Основные положения. В обзоре выделены пять ключевых метаболомных патогенетических осей МС: анаболическая резистентность, митохондриальная дисфункция, системное воспаление, инсулинорезистентность и лизосомальная недостаточность. Каждая из них представляет важное звено патогенеза, влияющее на развитие осложнений МС. Для каждой оси описаны характерные изменения низкомолекулярных метаболитов (например, аминокислот, органических кислот) и липидов, выявленные современными методами метаболомного анализа, и обсуждается их клиническое значение. Особое внимание уделено роли комбинированных панелей метаболитов, которые улучшают раннюю диагностику МС и преддиабета, позволяют стратифицировать риск осложнений (сахарный диабет 2-го типа, атеросклероз, неалкогольная жировая болезнь печени и др.) и мониторировать эффективность терапии. Отмечается, что метаболомные биомаркеры обладают высокой диагностической и прогностической ценностью, дополняя стандартные клинические показатели. Показано, что интеграция метаболомных данных с клиническими показателями повышает точность диагностики (например, объединение метаболомных маркеров с тестом толерантности к глюкозе увеличивает его прогностическую ценность). Разработка интегральных метаболомных индексов (таких, как MetSCORE) обеспечивает высокую точность распознавания МС (AUROC ~0,9). Метаболомные исследования подтверждают гетерогенность МС и позволяют выделять его подтипы в зависимости от преобладающих патофизиологических нарушений, что открывает перспективы прецизионной медицины.

Заключение. Метаболомный подход существенно расширяет возможности диагностики и персонализированной терапии пациентов с МС. Он позволяет выявлять скрытые метаболические нарушения на доклинической стадии заболевания, дополняя рутинные методы обследования. Для его внедрения в клиническую практику необходимы стандартизация методик метаболомного анализа, валидация метаболомных биомаркеров и интеграция мультиомиксных подходов, что обеспечит воспроизводимость результатов и их широкое применение в медицине.

1. Monnerie S., Comte B., Ziegler D., Morais J.A., Pujos-Guillot E., Gaudreau P. Metabolomic and lipidomic signatures of metabolic syndrome and its physiological components in adults: A systematic review. Sci Rep. 2020;10(1):669. DOI: 10.1038/s41598-019-56909-7

2. Prasun P. Mitochondrial dysfunction in metabolic syndrome. Biochim Biophys Acta Mol Basis Dis. 2020;1866(10):165838. DOI: 10.1016/j.bbadis.2020.165838

3. Кытикова О.Ю., Антонюк М.В., Кантур Т.А., Новгородцева Т.П., Денисенко Ю.К. Распространенность и биомаркеры метаболического синдрома. Ожирение и метаболизм. 2021;18(3):302–12. DOI: 10.14341/omet12704

4. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112(17):2735–52. DOI: 10.1161/CIRCULATIONAHA.105.169404

5. Menikdiwela K.R., Ramalingam L., Rasha F., Wang S., Dufour J.M., Kalupahana N.S., et al. Autophagy in metabolic syndrome: Breaking the wheel by targeting the renin-angiotensin system. Cell Death Dis. 2020;11(2):87. DOI: 10.1038/s41419-020-2275-9

6. Lent-Schochet D., McLaughlin M., Ramakrishnan N., Jialal I. Exploratory metabolomics of metabolic syndrome: A status report. World J Diabetes. 2019;10(1):23–36. DOI: 10.4239/wjd.v10.i1.23

7. Ramakrishanan N., Denna T., Devaraj S., Adams-Huet B., Jialal I. Exploratory lipidomics in patients with nascent metabolic syndrome. J Diabetes Complications. 2018;32(8):791–4. DOI: 10.1016/j.jdiacomp.2018.05.014

8. Reddy P., Leong J., Jialal I. Amino acid levels in nascent metabolic syndrome: A contributor to the pro-inflammatory burden. J Diabetes Complications. 2018;32(5):465–9. DOI: 10.1016/j.jdiacomp.2018.02.005

9. Lent-Schochet D., Silva R., McLaughlin M., Huet B., Jialal I. Changes to trimethylamine-N-oxide and its precursors in nascent metabolic syndrome. Horm Mol Biol Clin Investig. 2018;35(2):/j/hmbci.2018.35.issue-2/hmbci-2018-0015/hmbci-2018-0015.xml. DOI: 10.1515/hmbci-2018-0015

10. Qiu G., Zheng Y., Wang H., Sun J., Ma H., Xiao Y., et al. Plasma metabolomics identified novel metabolites associated with risk of type 2 diabetes in two prospective cohorts of Chinese adults. Int J Epidemiol. 2016;45(5):1507–16. DOI: 10.1093/ije/dyw221

11. Nilsson M.I., Xhuti D., de Maat N.M., Hettinga B.P., Tarnopolsky M.A. Obesity and metabolic disease impair the anabolic response to protein supplementation and resistance exercise: A retrospective analysis of a randomized clinical trial with implications for aging, sarcopenic obesity, and weight management. Nutrients. 2024;16(24):4407. DOI: 10.3390/nu16244407

12. Nilsson M.I., Dobson J.P., Greene N.P., Wiggs M.P., Shimkus K.L., Wudeck E.V., et al. Abnormal protein turnover and anabolic resistance to exercise in sarcopenic obesity. FASEB J. 2013;27(10):3905–16. DOI: 10.1096/fj.12-224006

13. Whytock K.L., Goodpaster B.H. Unraveling skeletal muscle insulin resistance: Molecular mechanisms and the restorative role of exercise circulation research. Circ Res. 2025;137(2):184–204. DOI: 10.1161/CIRCRESAHA.125.325532

14. Palmer N.D., Stevens R.D., Antinozzi P.A., Anderson A., Bergman R.N., Wagenknecht L.E., et al. Metabolomic profile associated with insulin resistance and conversion to diabetes in the Insulin Resistance Atherosclerosis Study. J Clin Endocrinol Metab. 2015;100(3):E463–8. DOI: 10.1210/jc.2014-2357

15. Bustos-Arriagada E., Arazo-Rusindo M.C., Rivera-Andrades G., Pérez-Bravo F., Castillo-Valenzuela O., BarrosVelázquez J., et al. Leucine intake and sarcopenia indicators of an elderly group from the metropolitan region, Santiago de Chile, who participated in the Program for Complementary Food in Older People (PACAM). Nutrients. 2024;16(20):3540. DOI: 10.3390/nu16203540

16. Nakajima H., Okada H., Kobayashi A., Takahashi F., Okamura T., Hashimoto Y., et al. Leucine and glutamic acid as a biomarker of sarcopenic risk in Japanese people with type 2 diabetes. Nutrients. 2023;15(10):2400. DOI: 10.3390/nu15102400

17. Conde-Pipó J., Mora-Fernandez A., Martinez-Bebia M., Gimenez-Blasi N., Lopez-Moro A., Latorre J.A., et al. Intermittent fasting: Does it affect sports performance? A systematic review. Nutrients. 2024;16(1):168. DOI: 10.3390/nu16010168

18. Tornero-Aguilera J.F., Jimenez-Morcillo J., Rubio-Zarapuz A., Clemente-Suárez V.J. Central and peripheral fatigue in physical exercise explained: A narrative review. Int J Environ Res Public Health. 2022;19(7):3909. DOI: 10.3390/ijerph19073909

19. Sheffield-Moore M., Dillon E.L., Randolph K.M., Casperson S.L., White G.R., Jennings K., et al. Isotopic decay of urinary or plasma 3-methylhistidine as a potential biomarker of pathologic skeletal muscle loss. J Cachexia Sarcopenia Muscle. 2014;5(1):19–25. DOI: 10.1007/s13539-013-0117-7

20. Curcio F., Ferro G., Basile C., Liguori I., Parrella P., Pirozzi F., et al. Biomarkers in sarcopenia: A multifactorial approach. Exp Gerontol. 2016;85:1–8. DOI: 10.1016/j.exger.2016.09.007

21. Toyoshima K., Nakamura M., Adachi Y., Imaizumi A., Hakamada T., Abe Y., et al. Increased plasma proline concentrations are associated with sarcopenia in the elderly. PLoS One. 2017;12(9):e0185206. DOI: 10.1371/journal.pone.0185206

22. Bloomgarden Z. Diabetes and branched-chain amino acids: What is the link? J Diabetes. 2018;10(5):350–2. DOI: 10.1111/1753-0407.12645

23. Wang T.J., Larson M.G., Vasan R.S., Cheng S., Rhee E.P., McCabe E., et al. Metabolite profiles and the risk of developing diabetes. Nat Med. 2011;17(4):448–53. DOI: 10.1038/nm.2307

24. Zhao X., Gang X., Liu Y., Sun C., Han Q., Wang G. Using metabolomic profiles as biomarkers for insulin resistance in childhood obesity: A systematic review. J Diabetes Res. 2016;2016:8160545. DOI: 10.1155/2016/8160545

25. Gall W.E., Beebe K., Lawton K.A., Adam K.P., Mitchell M.W., Nakhle P.J., et al.; RISC Study Group. Alpha-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population. PLoS One. 2010;5(5):e10883. DOI: 10.1371/journal.pone.0010883

26. Sonkar S.K., Verma J., Sonkar G.K., Gupta A., Singh A., Vishwakarma P., et al. Assessing the role of asymmetric dimethylarginine in endothelial dysfunction: Insights into cardiovascular risk factors. Cureus. 2025;17(1):e77565. DOI: 10.7759/cureus.77565

27. Muoio D.M. Metabolic inflexibility: When mitochondrial indecision leads to metabolic gridlock. Cell. 2014;159(6):1253–62. DOI: 10.1016/j.cell.2014.11.034

28. Goodpaster B.H., Sparks L.M. Metabolic flexibility in health and disease. Cell Metab. 2017;25(5):1027–36. DOI: 10.1016/j.cmet.2017.04.015

29. Koves T.R., Ussher J.R., Noland R.C., Slentz D., Mosedale M., Ilkayeva O., et al. Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metab. 2008;7(1):45–56. DOI: 10.1016/j.cmet.2007.10.013

30. Schooneman M.G., Vaz F.M., Houten S.M., Soeters M.R. Acylcarnitines: Reflecting or inflicting insulin resistance? Diabetes. 2013;62(1):1–8. DOI: 10.2337/db12-0466

31. White H.M. The role of TCA cycle anaplerosis in ketosis and fatty liver in periparturient dairy cows. Animals (Basel). 2015;5(3):793–802. DOI: 10.3390/ani5030384

32. Berthiaume J.M., Kurdys J.G., Muntean D.M., Rosca M.G. Mitochondrial NAD+/NADH redox state and diabetic cardiomyopathy. Antioxid Redox Signal. 2019;30(3):375–98. DOI: 10.1089/ars.2017.7415

33. Li X., Yang Y., Zhang B., Lin X., Fu X., An Y., et al. Lactate metabolism in human health and disease. Signal Transduct Target Ther. 2022;7(1):305. DOI: 10.1038/s41392-022-01151-3

34. Yamakado M., Tanaka T., Nagao K., Imaizumi A., Komatsu M., Daimon T., et al. Plasma amino acid profile associated with fatty liver disease and co-occurrence of metabolic risk factors. Sci Rep. 2017;7(1):14485. DOI: 10.1038/s41598-017-14974-w

35. Nowak C., Hetty S., Salihovic S., Castillejo-Lopez C., Ganna A., Cook N.L., et al. Glucose challenge metabolomics implicates medium-chain acylcarnitines in insulin resistance. Sci Rep. 2018;8(1):8691. DOI: 10.1038/s41598-018-26701-0

36. Jones T.E., Pories W.J., Houmard J.A., Tanner C.J., Zheng D., Zou K., et al. Plasma lactate as a marker of metabolic health: Implications of elevated lactate for impairment of aerobic metabolism in the metabolic syndrome. Surgery. 2019;166(5):861–6. DOI: 10.1016/j.surg.2019.04.017

37. Xu Z., Zhou Y., Xie R., Ning Z. Metabolomics uncovers the diabetes metabolic network: From pathophysiological mechanisms to clinical applications. Front Endocrinol (Lausanne). 2025;16:1624878. DOI: 10.3389/fendo.2025.1624878

38. Serena C., Ceperuelo-Mallafré V., Keiran N., Queipo-Ortuño M.I., Bernal R., Gomez-Huelgas R., et al. Elevated circulating levels of succinate in human obesity are linked to specific gut microbiota. ISME J. 2018;12(7):1642–57. DOI: 10.1038/s41396-018-0068-2

39. Xie J., Zhong F., Guo Z., Li X., Wang J., Gao Z., et al. Hyperinsulinemia impairs the metabolic switch to ketone body utilization in proximal renal tubular epithelial cells under energy crisis via the inhibition of the SIRT3/SMCT1 pathway. Front Endocrinol (Lausanne). 2022;13:960835. DOI: 10.3389/fendo.2022.960835

40. Fan L., Cacicedo J.M., Ido Y. Impaired nicotinamide adenine dinucleotide (NAD+) metabolism in diabetes and diabetic tissues: Implications for nicotinamide-related compound treatment. J Diabetes Investig. 2020;11(6):1403–19. DOI: 10.1111/jdi.13303

41. Semba R.D., Gonzalez-Freire M., Moaddel R., Sun K., Fabbri E., Zhang P., et al. Altered plasma amino acids and lipids associated with abnormal glucose metabolism and insulin resistance in older adults. J Clin Endocrinol Metab. 2018;103(9):3331–9. DOI: 10.1210/jc.2018-00480

42. Raza S., Rajak S, Yen P.M., Sinha R.A. Autophagy and hepatic lipid metabolism: Mechanistic insight and therapeutic potential for MASLD. NPJ Metab Health Dis. 2024;2(1):19. DOI: 10.1038/s44324-024-00022-5

43. Gunther S.H., Khoo C.M., Tai E.S., Sim X., Kovalik J.P., Ching J., et al. Serum acylcarnitines and amino acids and risk of type 2 diabetes in a multiethnic Asian population. BMJ Open Diabetes Res Care. 2020;8(1):e001315. DOI: 10.1136/bmjdrc-2020-001315

44. Owei I., Umekwe N., Stentz F., Wan J., Dagogo-Jack S. Association of plasma acylcarnitines with insulin sensitivity, insulin secretion, and prediabetes in a biracial cohort. Exp Biol Med (Maywood). 2021;246(15):1698–705. DOI: 10.1177/15353702211009493

45. Mohammadi M., Gozashti M.H., Aghadavood M., Mehdizadeh M.R., Hayatbakhsh M.M. Clinical Significance of serum IL-6 and TNF-α levels in patients with metabolic syndrome. Rep Biochem Mol Biol. 2017;6(1):74–9.

46. Rizo-Roca D., Henderson J.D., Zierath J.R. Metabolomics in cardiometabolic diseases: Key biomarkers and therapeutic implications for insulin resistance and diabetes. J Intern Med. 2025;297(6):584–607. DOI: 10.1111/joim.20090

47. Jornayvaz F.R., Shulman G.I. Diacylglycerol activation of protein kinase Cε and hepatic insulin resistance. Cell Metab. 2012;15(5):574–84. DOI: 10.1016/j.cmet.2012.03.005

48. Xu H., Chen R., Hou X., Li N., Han Y., Ji S. The clinical potential of 1,5-anhydroglucitol as biomarker in diabetes mellitus. Front Endocrinol (Lausanne). 2024;15:1471577. DOI: 10.3389/fendo.2024.1471577

49. Guasch-Ferré M., Hruby A., Toledo E., Clish C.B., Martínez-González M.A., Salas-Salvadó J., et al. Metabolomics in prediabetes and diabetes: A systematic review and meta-analysis. Diabetes Care. 2016;39(5):833–46. DOI: 10.2337/dc15-2251

50. White P.J., McGarrah R.W., Herman M.A., Bain J.R., Shah S.H., Newgard C.B. Insulin action, type 2 diabetes, and branched-chain amino acids: A two-way street. Mol Metab. 2021;52:101261. DOI: 10.1016/j.molmet.2021.101261

51. de Mello V.D., Sehgal R., Männistö V., Klåvus A., Nilsson E., Perfilyev A., et al. Serum aromatic and branched-chain amino acids associated with NASH demonstrate divergent associations with serum lipids. Liver Int. 2021;41(4):754–63. DOI: 10.1111/liv.14743

52. Hu C., Wang T., Zhuang X., Sun Q., Wang X., Lin H., et al. Metabolic analysis of early nonalcoholic fatty liver disease in humans using liquid chromatography-mass spectrometry. J Transl Med. 2021;19(1):152. DOI: 10.1186/s12967-021-02820-7

53. Mihalik S.J., Goodpaster B.H., Kelley D.E., Chace D.H., Vockley J., Toledo F.G., et al. Increased levels of plasma acylcarnitines in obesity and type 2 diabetes and identification of a marker of glucolipotoxicity. Obesity (Silver Spring). 2010;18(9):1695–700. DOI: 10.1038/oby.2009.510

54. Zhao X., Han Q., Liu Y., Sun C., Gang X., Wang G. The relationship between branched-chain amino acid related metabolomic signature and insulin resistance: A systematic review. J Diabetes Res. 2016;2016:2794591. DOI: 10.1155/2016/2794591

55. Gaggini M., Carli F., Rosso C., Buzzigoli E., Marietti M., Della Latta V., et al. Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance. Hepatology. 2018;67(1):145–58. DOI: 10.1002/hep.29465

56. Shao M., Ye Z., Qin Y., Wu T. Abnormal metabolic processes involved in the pathogenesis of non-alcoholic fatty liver disease (Review). Exp Ther Med. 2020;20(5):26. DOI: 10.3892/etm.2020.9154

57. Devaraj S., Singh U., Jialal I. Human C-reactive protein and the metabolic syndrome. Curr Opin Lipidol. 2009;20(3):182–9. DOI: 10.1097/MOL.0b013e32832ac03e

58. Jayakumar S., Loomba R. Review article: Emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications. Aliment Pharmacol Ther. 2019;50(2):144–58. DOI: 10.1111/apt.15314

59. Li Z., Wang L., Ren Y., Huang Y., Liu W., Lv Z., et al. Arginase: Shedding light on the mechanisms and opportunities in cardiovascular diseases. Cell Death Discov. 2022;8(1):413. DOI: 10.1038/s41420-022-01200-4

60. Perticone F., Sciacqua A., Maio R., Perticone M., Galiano Leone G., Bruni R., et al. Endothelial dysfunction, ADMA and insulin resistance in essential hypertension. Int J Cardiol. 2010;142(3):236–41. DOI: 10.1016/j.ijcard.2008.12.131

61. Seo S.K., Kwon B. Immune regulation through tryptophan metabolism. Exp Mol Med. 2023;55(7):1371–9. DOI: 10.1038/s12276-023-01028-7

62. Tsuji A., Ikeda Y., Yoshikawa S., Taniguchi K., Sawamura H., Morikawa S., et al. The tryptophan and kynurenine pathway involved in the development of immune-related diseases. Int J Mol Sci. 2023;24(6):5742. DOI: 10.3390/ijms24065742

63. Christensen M.H.E., Fadnes D.J., Røst T.H., Pedersen E.R., Andersen J.R., Våge V., et al. Inflammatory markers, the tryptophan-kynurenine pathway, and vitamin B status after bariatric surgery. PLoS One. 2018;13(2):e0192169. DOI: 10.1371/journal.pone.0192169

64. Tan K.M., Tint M.T., Kothandaraman N., Yap F., Godfrey K.M., Lee Y.S., et al. Association of plasma kynurenine pathway metabolite concentrations with metabolic health risk in prepubertal Asian children. Int J Obes (Lond). 2022;46(6):1128–37. DOI: 10.1038/s41366-022-01085-4

65. Monfort-Ferré D., Caro A., Menacho M., Martí M., Espina B., Boronat-Toscano A., et al. The gut microbiota metabolite succinate promotes adipose tissue browning in Crohn’s disease. J Crohns Colitis. 2022;16(10):1571– 83. DOI: 10.1093/ecco-jcc/jjac069

66. Rakhmat I.I., Nugraha G.I., Ariyanto E.F., Pratiwi Y.S., Linasari D., Fatimah S.N., et al. Strong association of metabolic parameters with ADMA and VCAM-1 in normo-weight subjects with metabolic syndrome. Diabetes Metab Syndr Obes. 2024;17:833–9. DOI: 10.2147/DMSO.S448650

67. Nishiyama Y., Otsuka T., Ueda M., Inagaki H., Muraga K., Abe A., et al. Asymmetric dimethylarginine is related to the predicted stroke risk in middle-aged Japanese men. J Neurol Sci. 2014;338(1–2):87–91. DOI: 10.1016/j.jns.2013.12.021

68. Tan Y., Liu X., Yang Y., Li B., Yu F., Zhao W., et al. Metabolomics analysis reveals serum biomarkers in patients with diabetic sarcopenia. Front Endocrinol (Lausanne). 2023;14:1119782. DOI: 10.3389/fendo.2023.1119782

69. Timmerman K.L., Volpi E. Endothelial function and the regulation of muscle protein anabolism in older adults. Nutr Metab Cardiovasc Dis. 2013;23 Suppl 1(0 1):S44–50. DOI: 10.1016/j.numecd.2012.03.013

70. Barrea L., Annunziata G., Muscogiuri G., Di Somma C., Laudisio D., Maisto M., et al. Trimethylamine-N-oxide (TMAO) as novel potential biomarker of early predictors of metabolic syndrome. Nutrients. 2018;10(12):1971. DOI: 10.3390/nu10121971

71. Oktaviono Y.H., Dyah Lamara A., Saputra P.B.T., Arnindita J.N., Pasahari D., Saputra M.E., et al. The roles of trimethylamine-N-oxide in atherosclerosis and its potential therapeutic aspect: A literature review. Biomol Biomed. 2023;23(6):936–48. DOI: 10.17305/bb.2023.8893

72. Vanholder R., Schepers E., Pletinck A., Nagler E.V., Glorieux G. The uremic toxicity of indoxyl sulfate and p-cresyl sulfate: A systematic review. J Am Soc Nephrol. 2014;25(9):1897–907. DOI: 10.1681/ASN.2013101062

73. Pallister T., Jackson M.A., Martin T.C., Zierer J., Jennings A., Mohney R.P., et al. Hippurate as a metabolomic marker of gut microbiome diversity: Modulation by diet and relationship to metabolic syndrome. Sci Rep. 2017;7(1):13670. DOI: 10.1038/s41598-017-13722-4

74. Saban Güler M., Arslan S., Ağagündüz D., Cerqua I., Pagano E., Berni Canani R., et al. Butyrate: A potential mediator of obesity and microbiome via different mechanisms of actions. Food Res Int. 2025;199:115420. DOI: 10.1016/j.foodres.2024.115420

75. Kasumov T., Edmison J.M., Dasarathy S., Bennett C., Lopez R., Kalhan S.C. Plasma levels of asymmetric dimethylarginine in patients with biopsy-proven nonalcoholic fatty liver disease. Metabolism. 2011;60(6):776–81. DOI: 10.1016/j.metabol.2010.07.027

76. Udovin L., Bordet S., Barbar H., Otero-Losada M., Pérez-Lloret S., Capani F. Metabolic syndrome and Parkinson’s disease: Two villains join forces. Brain Sci. 2025;15(7):706. DOI: 10.3390/brainsci15070706

77. Moon J., Kim O.Y., Jo G., Shin M.J. Alterations in circulating amino acid metabolite ratio associated with arginase activity are potential indicators of metabolic syndrome: The Korean Genome and Epidemiology Study. Nutrients. 2017;9(7):740. DOI: 10.3390/nu9070740

78. Ren Q., Sun Q., Fu J. Dysfunction of autophagy in high-fat diet-induced non-alcoholic fatty liver disease. Autophagy. 2024;20(2):221–41. DOI: 10.1080/15548627.2023.2254191

79. Zhang S., Peng X., Yang S., Li X., Huang M., Wei S., et al. The regulation, function, and role of lipophagy, a form of selective autophagy, in metabolic disorders. Cell Death Dis. 2022;13(2):132. DOI: 10.1038/s41419-022-04593-3

80. Araujo T.F., Cordeiro A.V., Vasconcelos D.A.A., Vitzel K.F., Silva V.R.R. The role of cathepsin B in autophagy during obesity: A systematic review. Life Sci. 2018;209:274–81. DOI: 10.1016/j.lfs.2018.08.024

81. Xu Q., Mariman E.C.M., Goossens G.H., Blaak E.E., Jocken J.W.E. Cathepsin gene expression in abdominal subcutaneous adipose tissue of obese/overweight humans. Adipocyte. 2020;9(1):246–52. DOI: 10.1080/21623945.2020.1775035

82. Tanaka S., Hikita H., Tatsumi T., Sakamori R., Nozaki Y., Sakane S., et al. Rubicon inhibits autophagy and accelerates hepatocyte apoptosis and lipid accumulation in nonalcoholic fatty liver disease in mice. Hepatology. 2016;64(6):1994–2014. DOI: 10.1002/hep.28820

83. Seo J.H., Koh J.M., Cho H.J., Kim H., Lee Y.S., Kim S.J., et al. Sphingolipid metabolites as potential circulating biomarkers for sarcopenia in men. J Cachexia Sarcopenia Muscle. 2024;15(6):2476–86. DOI: 10.1002/jcsm.13582

84. Field B.C., Gordillo R., Scherer P.E. The role of ceramides in diabetes and cardiovascular disease regulation of ceramides by adipokines. Front Endocrinol (Lausanne). 2020;11:569250. DOI: 10.3389/fendo.2020.569250

85. Ding L., Goossens G.H., Oligschlaeger Y., Houben T., Blaak E.E., Shiri-Sverdlov R. Plasma cathepsin D activity is negatively associated with hepatic insulin sensitivity in overweight and obese humans. Diabetologia. 2020;63(2):374–84. DOI: 10.1007/s00125-019-05025-2

86. Sen P., Govaere O., Sinioja T., McGlinchey A., Geng D., Ratziu V., et al. Quantitative modeling of human liver reveals dysregulation of glycosphingolipid pathways in nonalcoholic fatty liver disease. iScience. 2022;25(9):104949. DOI: 10.1016/j.isci.2022.104949

87. Gęgotek A., Skrzydlewska E. Lipid peroxidation products’ role in autophagy regulation. Free Radic Biol Med. 2024;212:375–83. DOI: 10.1016/j.freeradbiomed.2024.01.001

88. Bhore N., Bogacki E.C., O’Callaghan B., Plun-Favreau H., Lewis P.A., Herbst S. Common genetic risk for Parkinson’s disease and dysfunction of the endolysosomal system. Philos Trans R Soc Lond B Biol Sci. 2024;379(1899):20220517. DOI: 10.1098/rstb.2022.0517

89. Ma D., Molusky M.M., Song J., Hu C.R., Fang F., Rui C., et al. Autophagy deficiency by hepatic FIP200 deletion uncouples steatosis from liver injury in NAFLD. Mol Endocrinol. 2013;27(10):1643–54. DOI: 10.1210/me.2013-1153

90. Li Q.R., Xu H.Y., Ma R.T., Ma Y.Y., Chen M.J. Targeting autophagy: A promising therapeutic strategy for diabetes mellitus and diabetic nephropathy. Diabetes Ther. 2024;15(10):2153–82. DOI: 10.1007/s13300-024-01641-3

91. Drzewoski J., Hanefeld M. The current and potential therapeutic use of metformin — the good old drug. Pharmaceuticals (Basel). 2021;14(2):122. DOI: 10.3390/ph14020122